⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AVIR News
Atea Pharmaceuticals, Inc. Common Stock
Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus
globenewswire.com
AVIR
ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman
businesswire.com
COYA
AVIR
Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference
globenewswire.com
AVIR
Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
AVIR
Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
globenewswire.com
AVIR
Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025
globenewswire.com
AVIR
Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
globenewswire.com
AVIR